{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:24:02Z","timestamp":1789057442453,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/rhu.0b013e3181c8aa33","type":"journal-article","created":{"date-parts":[[2009,12,26]],"date-time":"2009-12-26T03:20:57Z","timestamp":1261797657000},"page":"38-39","source":"Crossref","is-referenced-by-count":22,"title":["An Atypical Presentation of Visceral Leishmaniasis Infection in a Patient With Rheumatoid Arthritis Treated With Infliximab"],"prefix":"10.1097","volume":"16","author":[{"given":"Konstantinos","family":"Kritikos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Haritatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Tsigkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Gounari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Skrapari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Gounaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Sioula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210207","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10096-008-0628-x","article-title":"Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.","volume":"28","author":"Garcia-Vidal","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R2-12-20210207","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists.","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R3-12-20210207","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"200","journal-title":"N Engl J Med"},{"key":"R4-12-20210207","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s10067-007-0660-8","article-title":"Listeria infections associated with infliximab: case reports.","volume":"26","author":"Kesteman","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R5-12-20210207","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10067-007-0775-y","article-title":"Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?","volume":"27","author":"Tektonidou","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R6-12-20210207","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R7-12-20210207","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R8-12-20210207","first-page":"891","article-title":"Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab.","volume":"3","author":"Fabre","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R9-12-20210207","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1157\/13059832","article-title":"Visceral leishmaniasis related to infliximab administration.","volume":"22","author":"Romani-Costa","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R10-12-20210207","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/rheumatology\/kel235","article-title":"Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab.","volume":"45","author":"Bassetti","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R11-12-20210207","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s10067-006-0356-5","article-title":"Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept.","volume":"26","author":"Bagalas","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R12-12-20210207","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/clind\/24.4.684","article-title":"Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.","volume":"24","author":"Berman","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R13-12-20210207","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01878488","article-title":"Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy.","volume":"7","author":"Ho","year":"1994","journal-title":"Biotherapy"},{"key":"R14-12-20210207","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4049\/jimmunol.144.1.278","article-title":"Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism.","volume":"144","author":"Green","year":"1990","journal-title":"J Immunol"},{"key":"R15-12-20210207","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4049\/jimmunol.153.2.768","article-title":"Role and effect of TNF-alpha inexperimental visceral leishmaniasis.","volume":"153","author":"Tumang","year":"1994","journal-title":"J Immunol"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00124743-201001000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:09:30Z","timestamp":1786039770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00124743-201001000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e3181c8aa33","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}